I should have enough to last.
SYMLIN, the company’s diabetes drug that is used in combination with insulin, is in a fairly small market — last quarter, it racked up just a tenth of the sales that big brother Byetta made. In order to increase sales of SYMLIN, Amylin got a pen formulation approved by the FDA, which it plans to launch in January. The pens make it easier for the patients to inject themselves and have been used as a way to increase sales in other products, such as Sanofi-Aventis‘ (NYSE: SNY) SoloSTAR Pen for injecting its insulin product.
Leave a Reply